

Malaria vaccine developer Sanaria Inc. receives the Technology Council of Maryland's Emerging Company of the Year Award.

Rockville, Maryland- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations.

http://techcouncilmd.com/News/tcmnews_080516.html

"All the members of the Sanaria team go to work every day with only one goal in mind, to develop a vaccine that will prevent millions of deaths from malaria," said Sanaria founder and CEO, Stephen L. Hoffman. "I am honored to accept this award on their behalf, and on behalf of our partners who have invested so much in us."

The PATH Malaria Vaccine Initiative, which is partnering with Sanaria Inc. to accelerate development of the company's novel malaria vaccine candidate, welcomed the news. "We at MVI are pleased at the recognition of our partner's efforts to establish a core platform technology for producing attenuated sporozoite malaria vaccines," said Director Dr. Christian Loucq.

The annual dinner and awards celebration was attended by Maryland Governor Martin O'Malley, additional state and local government representatives, and over 900 members of the Maryland technology and biotech industries.

About Sanaria Inc., The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against *Plasmodium falciparum*, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is <http://www.sanaria.com>.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to the use of funds to date to complete manufacturing the vaccine, and conduct initial clinical studies. Such risks and uncertainties include, but are not limited to, the Company's ability to raise funds on reasonable terms, the regulatory approval process, competitive products, and maintenance of its patent portfolio, among others.

Media contact: Adam Richman, Sanaria Inc., 9800 Medical Center Drive, Suite A209, Rockville, MD 20850 USA

Ph: +1-301-770-3222

Fax: +1-301-770-5554

Email: arichman@sanaria.com